CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 80 enrolled
Drug / intervention
TAK-931drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02699749
NCT02699749Phase 1Completed
CompareCT.gov

An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 (CDC7) Inhibitor, in Adult Patients With Advanced Nonhematologic Tumors

Millennium Pharmaceuticals, Inc.·interventional·Posted Mar 4, 2016·Updated Feb 21, 2021

In Brief

A Phase 1 clinical trial evaluating TAK-931 for Nonhematologic Neoplasms, Advanced. Completed, enrolled 80 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and maximum tolerated dose (MTD) of TAK-931 in participants with advanced nonhematologic tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonhematologic Neoplasms, Advanced
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 4, 2016
Enrollment StartMar 24, 2016
Primary CompletionDec 21, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.3 years ago

Interventions

TAK-931drug

TAK-931 oral capsules.